INTRODUCTION {#sec1}
============

*Clostridium difficile* infection (CDI) is the leading cause of hospital-acquired diarrhea in developed countries \[[@cit0001]-[@cit0004]\]. Metronidazole and vancomycin have been the primary treatment options in the management of CDI for the last few decades. Even though other antibiotics and monoclonal antibodies were recently approved for treatment of CDI \[[@cit0005], [@cit0006]\], the need for novel strategies is evident owing to therapeutic failure, vancomycin-resistant enterococci, high percentages of recurrences, and high costs in the case of newer drugs \[[@cit0005], [@cit0007]\].

Fecal microbiota transplantation (FMT) has proven to be a safe and effective treatment for refractory or relapsing CDI, although its use has been limited by practical barriers such as donor selection, product preparation, storage, delivery, and patient reluctance \[[@cit0008]-[@cit0010]\].

The methods of administration used, mainly colonoscopic delivery and nasoduodenal infusion are inconvenient both for patients and for healthcare facilities.This problem could be solved using a stable encapsulated preparation of standardized fecal microbiota that can be easily administered in daily clinical practice. In this sense, several groups have reported cases treated with encapsulated preparations that have proven as efficacious as other routes \[[@cit0011], [@cit0012]\].

Despite the enormous potential of FMT, its use in clinical practice continues to be very restricted in many European countries. FMT has not been widely used in Spain to date, with few published series \[[@cit0013]\]. Here, we describe our experience with FMT for treatment of recurrent CDI, including the novel approach based on orally administered fecal capsules.

MATERIAL AND METHODS {#sec2}
====================

**Setting, design, and study population.** Our institution is a large teaching hospital with 1,550 beds. The clinical microbiology laboratory receives samples from patients hospitalized at our center and from all the outpatient institutions in our catchment area. Systematic testing for toxigenic *C. difficile* was performed on all diarrheic stool samples from patients aged \>2 years.

**Definitions.** A CDI episode was defined as the presence of a positive result for toxigenic *C. difficile* testing and the presence of diarrhea (≥3 unformed stools in 24 hours) or colonoscopic findings demonstrating pseudomembranous colitis.

Severity of CDI was defined according to the guidelines of the Society of Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) \[[@cit0007]\].

An episode was considered a recurrence (R-CDI) if after recovery from a previous episode (at least 3 days without diarrhea and clinical improvement), symptoms returned and a stool sample separated from the former by between 15 and 60 days proved to be positive for toxigenic *C. difficile*. Episodes occurring more than 60 days after the previous one were not considered recurrences but new episodes.

Death was considered CDI-related when it was not attributable to other unrelated causes and occurred within 10 days of the CDI diagnosis and/or was due to well-known complications of CDI.

Primary resolution was defined as resolution of diarrhea without recurrence of CDI within 2 months after FMT; overall resolution was defined as resolution of diarrhea without recurrence of CDI within 2 months after a further FMT.

FMT procedure {#sec2.1}
-------------

### Donor {#s2a1}

A questionnaire based on the Food and Drug Administration (FDA) donor history questionnaire for blood and blood products was completed. Additional questionnaires were completed on gastrointestinal comorbidities (inflammatory bowel disease, irritable bowel syndrome, constipation or chronic diarrhea, history of major gastrointestinal surgery, gastrointestinal cancer, or polyposis) and factors that affect or may affect the composition of the intestinal microbiota (metabolic syndromes, systemic autoimmune diseases, atopic diseases \[asthma, eczema, eosinophilic alterations of the digestive tract\], and chronic pain syndromes). Donors were also asked about the recent intake of potent allergens when the donation was for a known recipient.

If donors passed these questionnaires, they were screened for human immunodeficiency virus (HIV), hepatitis A, human T-lymphotropic virus (HTLV) I/II, hepatitis B, hepatitis C, and syphilis in serum. Donor feces was screened for ova and parasites, *Giardia* antigen, *C. difficile*, *Listeria, Vibrio, Campylobacter, Yersinia, Salmonella, Shigella, E. coli* O157 H7 *, Helicobacter pylori* antigen *, Rotavirus, Norovirus, Adenovirus*, vancomycin-resistant *Enterococcus*, methicillin-resistant *S. aureus*, and extended-spectrum beta-lactamase--producing and carbapenem-resistant gram-negative microorganisms. Donors were reassessed for signs and symptoms of infectious diseases in the lapse between screening results and stool donation.

### Stool processing for FMT {#s2a2}

To be accepted for processing, stools had to be properly collected from suitable donors (preferably within \<6 hours after evacuation, always within 24 hours of evacuation), not contaminated (with water, urine, or blood), and complete (acceptable minimum, 50 grams)

A fecal suspension was generated in saline without preservatives, using a commercial blender during the study period (2014-August 2016); a Stomacher 4000 was used to homogenize samples from September 2016 onward. The fecal suspension was filtered, centrifuged, and resuspended in concentrated form in sterile saline with 12.5% glycerol as cryoprotectant for frozen forms.

For the capsule formulation, the fecal suspension was further centrifuged to increase the concentration. The bacterial pellet was then resuspended with saline and 12.5% glycerol. The resulting suspension was double-encapsulated in hypromellose capsules (sizes 0/00, Capsugel, Cambridge, MA, USA) and stored at --80°C.

### Recipient {#s2a3}

Antibiotic treatment was discontinued at least 48 hours before the FMT procedure. On the day before the procedure, all patients received a light dinner and those receiving FMT via nasojejunal also received omeprazole 40 mg. After a 12-hour fast, the donor's intestine was prepared with Bohm evacuating solution (4L Macrogol 4000). On the morning of the procedure in the case of nasojejunal delivery, an x-ray was performed to verify that the probe was correctly inserted and a further 40 mg of omeprazole was administered. A routine blood analysis was also performed on all cases the morning before the procedure.

After the procedure, a 4-6 hour fast was recommended. From 2017, blood cultures and blood analysis were performed systematically on the first and second day after the FMT procedure. Follow-up has been continuous since then.

**Clinical data.** The demographic data collected included age, sex, and ethnicity. Clinical data regarding the underlying condition were recorded using the McCabe and Jackson score for prognosis of underlying diseases; comorbidity was graded according to the Charlson index \[[@cit0014], [@cit0015]\]. As a referral center, some of the patients included in this case series received medical care and treatment at other medical facilities prior to receiving FMT at our institution. We made every effort to obtain the medical records and previous treatment courses.

The clinical data recorded for the CDI episodes were severity of the CDI episode, and antibiotic treatment for the CDI episode. Outcomes such as treatment failure, recurrence, mortality, CDI-related mortality, FMT, and FMT procedure--related mortality were also recorded.

**Microbiome analysis.** Selected samples from donors and recipients underwent microbiome analysis. Total DNA was extracted from fecal samples using the QIAamp DNA Stool mini kit (QIAGEN; Hilden, Germany) according to the manufacturer's protocol and including a homogenization step. The sample was homogenized in FastPrep-24 (MPBio, California, USA) with Lysing Matrix E tubes (MPBio, California, USA) twice at 6.5 m/s for 45 seconds. The hypervariable V4 region of the 16s rRNA gene was amplified by PCR with 515-806 primers tailed with sequences to incorporate Illumina flow cell adapters and indexing barcodes.

Primer dimers and low-molecular-weight products were removed using Agencourt Ampure Beads (Beckman Coulter, California, USA), and samples were quantified and quality checked for amplicon size using the Agilent TapeStation (Agilent; California, USA). Amplicons were equimolar pooled and sequenced (2 × 250) on a Miseq platform (Illumina; California, USA) according to standard protocols. Mothur's bioinformatic pipeline was followed for data analysis.

**Data analysis.** Data were analyzed using PASW Statistics for Windows, Version 18.0 (SPSS Inc, Illinois, USA). Qualitative variables appear with their frequency distribution. Quantitative variables are expressed as the median and interquartile range (IQR). Groups were compared using the Fisher exact test for categorical variables and the Mann-Whitney or *t* test for continuous variables. A p value \<0.05 was considered significant.

**Ethical Issues.** This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón (number MICRO.HGUGM.2016-029). Informed consent for FMT was obtained from all patients as well as from donors. Since FMT policy and legislation differ from country to country, we consulted the Spanish Agency of Medicines and Medical Devices (AEMPS), which is the national authority for regulating pharmaceutical products. The AEMPS noted that FMT does not fall under the category of pharmaceutical products. The Spanish National Transplant Organization (ONT) was also consulted, and did not consider the procedure a tissue or organ transplant.

RESULTS {#sec3}
=======

During the study period, the microbiology laboratory identified 1,447 patients with a CDI episode, which was recurrent in 236 (16.3%). Further recurrences were detected, as follows: 65 patients had 2 R-CDI episodes, 13 had 3 R-CDI episodes, 4 had 4 R-CDI episodes, 2 had 5 R-CDI episodes, and 1 had 6 R-CDI episodes. FMT for patients with R-CDI was performed in 13 cases: 9 from our center and 4 who were referred to us from other centers. Our FMT program was initially designed for patients with 3 or more R-CDI episodes until March of 2017, when we decided to include patients with 2 R-CDI episodes.

The demographic and clinical characteristics of the CDI patients who underwent FMT are shown in [table 1](#t0001){ref-type="table"}. Most patients were female (76.9%), and the median age was 75.0 years. The most frequent underlying disease was malignancy (53.8%), followed by endocrine disease (38.5%). The median Charlson score was 3.0 (IQR 1.0-5.5).

###### 

Demographic and clinical characteristics of patients with Clostridium difficile infection treated with fecal microbiota transfer

  Patient number   Age   Sex   Referred patient   Underlying conditions categories                                                                         McCabe Jackson   Charlson Comorbidity Index   Number of R-CDI episodes
  ---------------- ----- ----- ------------------ -------------------------------------------------------------------------------------------------------- ---------------- ---------------------------- --------------------------
  1                84    F     NO                 Malignancy, cardiovascular, liver                                                                        2                6                            7
  2                82    M     NO                 Malignancy, cardiovascular, respiratory, gastrointestinal, hematologic, rheumatologic, nephro-urologic   3                7                            3
  3                93    F     NO                 Cardiovascular, endocrine, nephro-urologic                                                               3                2                            4
  4                58    F     YES                Cardiovascular, gastrointestinal, liver                                                                  3                2                            3
  5                75    M     NO                 Malignancy, nephro-urologic                                                                              3                1                            4
  6                24    M     NO                 Gastrointestinal                                                                                         3                1                            3
  7                60    F     NO                 Malignancy, liver                                                                                        2                5                            2
  8                72    F     NO                 Malignancy, liver, endocrine                                                                             2                5                            4
  9                70    F     YES                Solid organ transplant, endocrine                                                                        3                3                            2
  10               62    F     YES                Malignancy                                                                                               3                6                            3
  11               89    F     NO                 Endocrine, metabolic                                                                                     3                1                            2
  12               90    F     NO                 Malignancy, respiratory, endocrine, nephro-urologic                                                      3                4                            3
  13               93    F     YES                Rheumatologic                                                                                            3                0                            2

R-CDI. Recurrent Clostridium difficile infection; F. female; M. male.

The median number of CDI previous recurrences was 3.0 (IQR 2.0-4.0). In patients that were not transferred from other centers, most of the initial CDI episodes were considered mild to moderate (66.7%), 22.2% were considered severe, and 11.1% severe complicated. Three cases were due to *C. difficile* ribotype 027. We found no significant differences with respect to primary resolution rates (p=0.464) or overall resolution rates (p=1.000) between episodes caused by *C. difficile* ribotype 027 and non-027 ribotypes.

As for previous treatments for CDI, the initial episodes were treated with metronidazole (53.8%), 2 were treated with a combination of metronidazole and vancomycin, 3 were treated with vancomycin taper, and 1 with vancomycin alone. The most frequent treatments for R-CDI were vancomycin taper and fidaxomicin. Antibiotic treatments for R-CDI episodes are summarized in [table 2](#t0002){ref-type="table"}.

###### 

Patients' antibiotic treatments for recurrent Clostridium difficile infection episodes previous to fecal microbiota transfer

  Patient number   1st R-CDI treatment            2nd R-CDI treatment                                       3rd R-CDI treatment             4th R-CDI treatment               5th R-CDI treatment   6th R-CDI treatment   7th R-CDI treatment
  ---------------- ------------------------------ --------------------------------------------------------- ------------------------------- --------------------------------- --------------------- --------------------- ---------------------
  1                Vancomycin                     Vancomycin taper                                          Vancomycin taper                Fidaxomicin                       Vancomycin taper      Metronidazole         Vancomycin taper
  2                Vancomycin taper               Fidaxomicin                                               Vancomycin                                                                                                    
  3                Vancomycin taper               Vancomycin taper                                          Fidaxomicin                     Vancomycin                                                                    
  4                Metronidazole                  Vancomycin                                                Fidaxomicin, vancomycin taper                                                                                 
  5                Vancomycin, vancomycin taper   Combined metronidazole and Vancomycin, Vancomycin taper   Fidaxomicin                     Fidaxomicin, Tapered vancomycin                                               
  6                Vancomycin taper               Metronidazole, vancomycin taper                           Fidaxomicin                                                                                                   
  7                Fidaxomicin                    Vancomycin taper                                                                                                                                                        
  8                Vancomycin taper               Fidaxomicin                                               Vancomycin taper                Vancomycin taper                                                              
  9                Vancomycin taper               Fidaxomicin                                                                                                                                                             
  10               Vancomycin                     Fidaxomicin                                               Metronidazole                                                                                                 
  11               Fidaxomicin                    Vancomycin taper                                                                                                                                                        
  12               Vancomycin                     Fidaxomicin                                               Vancomycin taper                                                                                              
  13               Fidaxomicin                    Vancomycin taper                                                                                                                                                        

R-CDI. Recurrent Clostridium difficile infection. Metronidazole: Metronidazole 500mg/8 hours 10 days; Vancomycin: Vancomycin 125mg/6 hours 10days; Vancomycin taper: Vancomycin in tapered regimen for a minimum of 6-8 weeks; Fidaxomicin: Fidaxomicin 200mg/12hours 10 days

Donors were family members in 30.8% of cases and unrelated healthy donors from our stool bank in 69.2%. Two procedures (15.4%) were performed with fresh donations, and 84.6% were performed from frozen preparations. Data regarding the FMT specifications are shown in [table 3](#t0003){ref-type="table"}. Six FMT were performed via nasojejunal tube, 5 were performed via oral capsules, and 2 were performed via colonoscopy.

###### 

Fecal microbiota procedure and patients' outcome

  Patient number   Number of FMT   Administration   Fresh or frozen   Quantity                  FMT- related complications   Primary outcome resolution   Secondary outcome (overall resolution)
  ---------------- --------------- ---------------- ----------------- ------------------------- ---------------------------- ---------------------------- ----------------------------------------
  1                1               Nasojejunal      Fresh             200ml                     NA\*                         NA\*                         NA\*
  2                1               Nasojejunal      Fresh             200ml                     NO                           YES                          YES
  3                1               Nasojejunal      Frozen            200ml                     NO                           YES                          YES
  4                1               Nasojejunal      Frozen            120ml                     NO                           YES                          YES
  5                1               Nasojejunal      Frozen            \-                        NO                           YES                          YES
  6                1               Nasojejunal      Frozen            \-                        NO                           NO                           NO\*\*
  7                1               Colonoscopy      Frozen            300ml                     YES (*E. coli* bacteremia)   YES                          YES
  8                1               Colonoscopy      Frozen            200ml                     NO                           YES                          YES
  9                1               Oral capsules    Frozen            15 capsules/day; 2 days   NO                           YES                          YES
  10               1               Oral capsules    Frozen            15 capsules/day; 2 days   NO                           YES                          YES
  11               1               Oral capsules    Frozen            15 capsules/day; 2 days   NO                           YES                          YES
  12               2               Oral capsules    Frozen            15 capsules/day; 2 days   NO                           NO                           YES
  13               1               Oral capsules    Frozen            15 capsules/day; 2 days   NO                           YES                          YES

NA\*: Not applicable, the patient died of causes not related to FMT within a week of FMT, and outcome could not be assessed. NO\*\*: The patient did not receive any additional transplants.

At the time of writing, the chart analysis revealed the median follow-up time to be 6 months (IQR 6-17 months). One of the patients died of causes not related to FMT within a week of treatment and was therefore not included in the analysis of FMT outcome since it was not possible to assess the outcome. The primary resolution rate was 83.3% (10/12). The 2 patients who were considered to have R-CDI or in whom R-CDI could not be ruled out developed diarrhea within 2 months after FMT. One had a toxigenic *C. difficile*--positive stool sample in the context of an underlying inflammatory bowel disease and was treated with vancomycin taper. In the other patient, vancomycin was initiated prior to obtaining a fecal sample for testing, an additional FMT was performed and no further recurrences were observed, yielding an overall resolution rate of 91.7%. FMT-related complications occurred in only 1 patient. In this patient, there were no complications in the following 48 hours after the fecal transplant. However, at 72 hours post-transplant, the patient presented with generalized abdominal pain and subsequently a febrile peak of 38ºC, blood cultures were extracted, which were positive for *E. coli*. The patient was successfully treated and was discharged on the day +10 post-transplant.

[Figure 2](#f0002){ref-type="fig"} shows the results of the microbiome analysis that was performed in the donor stool and in the recipient's stool (patient \#12) soon after FMT (day +1), as well as in a stool sample after the patient developed diarrhea (day +19). As can be seen, patient \#12 did not seem to have engrafted the donation, and the microbiota pattern was altered within the episode of R-CDI diarrhea, with an increase in the amount of *Proteobacteria* and a decrease in *Bacteroidetes*.

![Microbiome analysis for patient \#12 and its donor](revespquimioter-31-411-g001){#f0001}

DISCUSSION {#sec4}
==========

We report our experience and results for 13 FMT-treated patients with significant comorbidities, 5 of whom were treated with a capsule formulation. Of the 13 patients with R-CDI, FMT was successful in 12 (91.7%). These results are similar to those found in the literature, with most studies reporting overall cure rates above 90% \[[@cit0016]\].

Most of the cases in the present study were performed with frozen material. Selecting frozen FMT is now a reasonable option owing to its convenience and data showing that this approach is as effective as fresh FMT. A recent meta-analysis showed that frozen FMT was as effective as fresh FMT, both for primary resolution and overall effective rate (95%) \[[@cit0017]\].

![Oral capsules for fecal transplant](revespquimioter-31-411-g002){#f0002}

The few studies that describe FMT in the form of capsules \[[@cit0011], [@cit0018], [@cit0019]\] report an overall resolution rates above 90%. In our series, we observed a primary resolution rate of 80% and an overall resolution rate of 100% with frozen capsules. A very recent study by Kao et al. compared capsules with colonoscopic delivery, although no significant differences were observed between the groups, with a 96.2% resolution rate in both the capsule group (51/53) and the colonoscopy group (50/52). The FMT capsule delivery group had a better rating in terms of the pleasantness of the FMT procedure compared to colonoscopic delivery \[[@cit0012]\].

Few data have been reported on FMT in patients with significant comorbidities, as is the case with immunocompromised patients, and data on FMT performed on cirrhotic patients are even scarcer \[[@cit0020], [@cit0021]\]. Cirrhotic patients have been excluded from many studies owing to the suspected risk of infectious complications. Published data from case series to date suggest that FMT is safe and effective, even for immunocompromised patients \[[@cit0020], [@cit0022]\]. In our series, we included patients with significant underlying hematological diseases and cirrhotic patients. The outcome was generally favorable.

Although less is known about the application of FMT for the treatment of severe or complicated CDI, there is evidence supporting the use of FMT in these cases \[[@cit0023]\]. Lagier et al. \[[@cit0024]\] reported an outbreak of CDI due to ribotype 027 in Marseille that had been treated with early fecal transplantation. The authors observed that it was associated with a significantly reduced mortality rate \[[@cit0024]\]. In our series, we found no significant differences in outcome between episodes caused by ribotype 027 strains and ribotype non-027 strains with respect to the outcome of FMT, however we had a very limited number of cases due to ribotype 027.

Bacterial diversity among patients with recurrent CDI is noticeably lower than that of healthy subjects \[[@cit0025]\], with higher relative amounts of *Proteobacteria* and *Firmicutes* phyla, and lower relative abundance of *Bacteroidetes* \[[@cit0026]\]. Increased abundancy of *Gammaproteobacteria* has been associated with more recurrences \[[@cit0026]-[@cit0028]\]. We observed a similar situation in the patient who had R-CDI after 1 fecal transplant. The data from the microbiome analysis revealed that the recipient did not seem to have engrafted the donation and that the microbiota pattern was altered within the R-CDI diarrhea episode, with an increase in *Proteobacteria* to the detriment of *Bacteroidetes*.

Our study is limited by the fact that it is a single-center study with a limited number of patients. However, to the best of our knowledge, it is the first such report addressing the capsule FMT formulation in Spain.

In conclusion, in our cohort, FMT appeared to be a safe and effective treatment for R-CDI in patients with significant comorbidities. Delivery of FMT in capsules was as safe and effective as other FMT delivery methods and was well tolerated by patients. In our experience, it seems reasonable to include the FMT capsule formulation in the general hospital routine. Moreover, future directions for FMT should encompass the use of lyophilized FMT capsules that can be administered orally in an even more convenient therapeutic regimen.
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